Skip to main
PODD

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 38%
Buy 19%
Hold 38%
Sell 5%
Strong Sell 0%

Bulls say

Insulet is facing some supply chain and manufacturing dependencies that could impact distribution and sales, but the recent launch of its Omnipod 5 automated insulin delivery system shows potential for future growth. Despite recent concerns about lower utilization and retention trends in the US Type 2 population, strong international momentum and profitability, coupled with the company's efforts to improve commercial execution, warrant a neutral rating. There are some risks to achieving the company's price target, such as competition, technology risk, and geopolitical risk, but overall, Insulet's unique product and potential for international growth provide a positive outlook.

Bears say

Insulet is facing several significant challenges that could negatively impact their financial performance and stock value. These challenges include increased competition from new entrants in the tubeless insulin pump market, potential loss of market share in the T2D population due to lower utilization and retention trends, and potential cybersecurity threats for their devices. These challenges, coupled with uncertainty surrounding management's credibility, may lead to lower revenue growth and profitability for the company in the coming years.

Insulet (PODD) has been analyzed by 21 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 19% recommend Buy, 38% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 21 analysts, Insulet (PODD) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $193.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $193.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.